ABOUT AVIDITY
Our mission is to profoundly improve people’s lives by delivering a new class of RNA therapeutics – AOCs. Our proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Our advancing and expanding pipeline includes multiple skeletal muscle programs. We are also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution.
News Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
January 7, 2020
SAN DIEGO, Jan. 7, 2020 /PRNewswire/ — Avidity Biosciences (Avidity) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020 in...
-
November 13, 2019
La Jolla, Calif., November 13, 2019 (BUSINESS WIRE) – Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) for the treatment of rare muscle...
-
October 1, 2019
La Jolla, California, October 1, 2019 (PRNewswire) — Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the...
-
September 12, 2019
La Jolla, California, September 12, 2019 (PRNEWSWIRE) – Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), today announced that...
-
August 22, 2019
La Jolla, California, August 22, 2019 (PR NEWSWIRE) – Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) focused in rare muscle disorders and...
-
April 22, 2019Collaboration will pursue therapeutic targets focused on immunology and other indications
INDIANAPOLIS, IN, and LA JOLLA, CA — April 22, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Avidity Biosciences, Inc. today announced a global licensing and research collaboration...
-
January 3, 2019
LA JOLLA, CA — January 3, 2019 – Arthur A. Levin, Ph.D, executive vice president of research and development at Avidity Biosciences LLC, a biotechnology company advancing Antibody-...
-
October 17, 2018Investment advances pre-clinical development of novel exon skipping therapies for treatment of patients with Duchenne muscular dystrophy
LA JOLLA, Calif. (October 17, 2018) — Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates,...
-
January 5, 2017
LA JOLLA, CA — January 5, 2017 – Avidity Biosciences LLC, a biotechnology company advancing antibody-siRNA conjugates (ASCs) as a new class of precision medicines, today announced a...
-
January 5, 2017
LA JOLLA, CA — January 5, 2017 – Avidity Biosciences today announced the completion of a $16 million Series B financing round to support the development of its Antibody-siRNA Conjugate (ASC)...